Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data...
Read more: Further CYP-001 GvHD Clinical Data Published in Nature Medicine
Hashtag.net.au
In today’s complex healthcare landscape, striking the right balance between operational efficiency and regulatory compliance is more than a best practice—it’s a necessity. Healthcare organisations m...
Hashtag.net.au
Among the myriad of advancements in the field of dentistry, none have impacted as radically as dental implants. A last option not long ago, today, implants are the go-to solution for millions of ind...
Hashtag.net.au
A warm, welcoming smile can change how you see yourself and how others see you. But to so many, crooked or uneven teeth will obstruct smiling openly. Modern cosmetic dentistry has answers, though, t...